Reporting of paclitaxel-induced peripheral neuropathy symptoms to clinicians among women with breast cancer: a qualitative study | Zendy

Teresa M. Salgado | Zendy; Caroline Quinn | Zendy; Emily K. Krumbach | Zendy; Iris Wenceslao | Zendy; Martha M. Gonzalez | Zendy; Holly L. Reed | Zendy; Jillian G. Syverson | Zendy; Rebecca Etz | Zendy; Kiran Vangipuram | Zendy; Melissa R. Barker | Zendy; N. Lynn Henry | Zendy; Karen B. Farris | Zendy; Daniel L. Hertz | Zendy

Open Access

Reporting of paclitaxel-induced peripheral neuropathy symptoms to clinicians among women with breast cancer: a qualitative study

Author(s) -

Teresa M. Salgado,

Caroline Quinn,

Emily K. Krumbach,

Iris Wenceslao,

Martha M. Gonzalez,

Holly L. Reed,

Jillian G. Syverson,

Rebecca Etz,

Kiran Vangipuram,

Melissa R. Barker,

N. Lynn Henry,

Karen B. Farris,

Daniel L. Hertz

Publication year - 2020

Publication title -

supportive care in cancer

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 1.133

H-Index - 112

eISSN - 1433-7339

pISSN - 0941-4355

DOI - 10.1007/s00520-019-05254-6

Subject(s) - chemotherapy induced peripheral neuropathy , medicine , discontinuation , nursing research , qualitative research , breast cancer , pain medicine , observational study , peripheral neuropathy , family medicine , oncology , cancer , psychiatry , nursing , social science , anesthesiology , endocrinology , sociology , diabetes mellitus

Cases of chemotherapy-induced peripheral neuropathy (CIPN) under-reporting have been sporadically described in the literature, but no studies have focused on actively examining this behavior. Our primary aim was to identify women who purposefully under-reported CIPN, along with reasons for doing so. A secondary aim was to explore factors enabling or hindering communication of CIPN to clinicians.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research